These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33518672)

  • 1. Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus.
    Shioya H; Inagaki Y; Hiraizumi K; Hoshino T; Kurata H; Habashita H; Sato K; Nakade S
    Biol Pharm Bull; 2021; 44(2):188-196. PubMed ID: 33518672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model.
    Komiya T; Gohda M; Shioya H; Katsumata S
    J Pharmacol Exp Ther; 2021 Feb; 376(2):250-260. PubMed ID: 33257316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P
    Kurata H; Kusumi K; Otsuki K; Suzuki R; Kurono M; Komiya T; Hagiya H; Mizuno H; Shioya H; Ono T; Takada Y; Maeda T; Matsunaga N; Kondo T; Tominaga S; Nunoya KI; Kiyoshi H; Komeno M; Nakade S; Habashita H
    J Med Chem; 2017 Dec; 60(23):9508-9530. PubMed ID: 29120624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.
    Komiya T; Sato K; Shioya H; Inagaki Y; Hagiya H; Kozaki R; Imai M; Takada Y; Maeda T; Kurata H; Kurono M; Suzuki R; Otsuki K; Habashita H; Nakade S
    Clin Exp Immunol; 2013 Jan; 171(1):54-62. PubMed ID: 23199323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppressive effects of a selective inducible nitric oxide synthase (iNOS) inhibitor on pancreatic beta-cell dysfunction.
    Kato Y; Miura Y; Yamamoto N; Ozaki N; Oiso Y
    Diabetologia; 2003 Sep; 46(9):1228-33. PubMed ID: 12898012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-phosphate receptor modulator ONO-4641 stimulates CD11b
    Asakura T; Ishii M; Namkoong H; Suzuki S; Kagawa S; Yagi K; Komiya T; Hashimoto T; Okamori S; Kamata H; Tasaka S; Kihara A; Hegab AE; Hasegawa N; Betsuyaku T
    Mucosal Immunol; 2018 Nov; 11(6):1606-1620. PubMed ID: 30116000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
    Ammon HPT
    Phytomedicine; 2019 Oct; 63():153002. PubMed ID: 31301539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effect of Ninjin-to (Ren-Shen-Tang), a Kampo (Japanese traditional) formulation, on spontaneous autoimmune diabetes in non-obese diabetic (NOD) mice.
    Kobayashi T; Song QH; Hong T; Kitamura H; Cyong JC
    Microbiol Immunol; 2000; 44(4):299-305. PubMed ID: 10832976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
    Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M
    Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice.
    Kaino Y; Hirai H; Ito T; Kida K
    Diabetes Res Clin Pract; 1996 Sep; 34(1):7-11. PubMed ID: 8968685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.
    Yang ZD; Chen M; Wu R; McDuffie M; Nadler JL
    Diabetologia; 2002 Sep; 45(9):1307-14. PubMed ID: 12242464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.
    Hancock WW; Polanski M; Zhang J; Blogg N; Weiner HL
    Am J Pathol; 1995 Nov; 147(5):1193-9. PubMed ID: 7485382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive effects of andrographolide on the development of diabetes in autoimmune diabetic NOD mice by inducing immune tolerance.
    Zhang C; Gui L; Xu Y; Wu T; Liu D
    Int Immunopharmacol; 2013 Aug; 16(4):451-6. PubMed ID: 23707775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NO-mediated cytotoxicity contributes to multiple low-dose streptozotocin-induced diabetes but not to NOD diabetes.
    Yasuda H; Jin Z; Nakayama M; Yamada K; Kishi M; Okumachi Y; Arai T; Moriyama H; Yokono K; Nagata M
    Diabetes Res Clin Pract; 2009 Feb; 83(2):200-7. PubMed ID: 19117633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effect of gangliosides on non-obese diabetic mice.
    Papaccio G; Chieffi Baccari G; Mezzogiorno V
    Acta Anat (Basel); 1993; 147(3):168-73. PubMed ID: 8213041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the non-obese diabetic (NOD) mouse.
    Durant S; Alves V; Coulaud J; El Hasnaoui A; Dardenne M; Homo-Delarche F
    J Autoimmun; 1995 Dec; 8(6):875-85. PubMed ID: 8824712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice.
    Choi MS; Jung UJ; Yeo J; Kim MJ; Lee MK
    Diabetes Metab Res Rev; 2008; 24(1):74-81. PubMed ID: 17932873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte vaccination protects prediabetic non-obese diabetic mice from developing diabetes mellitus.
    Gearon CL; Hussain MJ; Vergani D; Peakman M
    Diabetologia; 1997 Dec; 40(12):1388-95. PubMed ID: 9447945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice.
    Rabinovitch A; Suarez WL; Power RF
    J Lab Clin Med; 1993 Apr; 121(4):603-7. PubMed ID: 8454942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.
    Yang Z; Chen M; Fialkow LB; Ellett JD; Wu R; Brinkmann V; Nadler JL; Lynch KR
    Clin Immunol; 2003 Apr; 107(1):30-5. PubMed ID: 12738247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.